 TRACON Pharmaceuticals NASDAQ:TCON Inc reported that its partners had announced that envafolimab KN035 had received marketing authorization from the Chinese National Medical Products Administration NMPA - the first approval of a subcutaneously administered checkpoint inhibitor. Envafolimab has been given the go-ahead for adults with microsatellite instability-high MSI-H, or deficient MisMatch Repair dMMR advanced solid tumors. 